There are currently 1503 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Texas Oncology- Sammons CC at Baylor, Dallas, Texas
Conditions: Chronic Myeloid Leukemia
Brief Prolonged Exposure Therapy Versus Clinical Standard to Reduce Posttraumatic Stress Post Spinal Cord Injury
Recruiting
This study will examine the use brief prolonged exposure (Brief PE) therapy compared to standard clinical care to reduce posttraumatic distress among people who have had a spinal cord injury and are receiving rehabilitation in an inpatient setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2022
Locations: Baylor Institute for Rehabilitation, Dallas, Texas
Conditions: Spinal Cord Injuries, PTSD, Post-Traumatic Stress Disorder
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Recruiting
Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2021
Locations: Dallas VA Medical Center, Dallas, Texas
Conditions: Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma